Abstract

Human Metapneumovirus (HMPV) is a significant respiratory pathogen, primarily affecting young children, the elderly, and immunocompromised individuals. In the postCOVID-19 era, its epidemiology, clinical presentation, and public health implications have undergone notable changes. This review explores the interplay between HMPV and the disruptions caused by the pandemic, including shifts in seasonal trends, altered population immunity, and overlapping symptoms with COVID-19, which complicate diagnosis. The lack of rapid diagnostic tests and limited awareness among healthcare providers further hinders timely detection and management. Current treatment remains supportive, as challenges in developing targeted antiviral therapies and vaccines persist due to HMPV’s genetic diversity and complex pathogenesis. Insights from the pandemic, including the effectiveness of public health measures and surveillance systems, underscore the need for integrated strategies to manage concurrent viral epidemics. The review also highlights the potential impact of climate change on HMPV seasonality and the critical role of global collaboration in advancing diagnostics, therapeutics, and vaccines. Addressing these challenges is essential to mitigate the burden of HMPV and improve outcomes for at-risk populations. Key Messages: The post-COVID-19 era has reshaped HMPV’s epidemiology, presenting new challenges in diagnosis, management, and prevention. Improved surveillance, research on vaccines, and integrated public health strategies are essential for mitigating future outbreaks.

• 1.   Van den Hoogen B.G., de Jong J.C., Groen J., Kuiken T., de Groot R., Fouchier R.A., Osterhaus A.D. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature medicine. 2001 Jun; 7(6):719-24.
• 2.   Esposito S., Mastrolia M.V. Metapneumovirus infections and respiratory complications. InSeminars in respiratory and critical care medicine 2016 Aug (Vol. 37, No. 04, pp. 512-521). Thieme Medical Publishers.
• 3.   Ji W., Chen Y., Han S., Dai B., Li K., Li S., Li Z., Chen S., Zhang Y., Zhang X., Wang Q. Clinical and epidemiological characteristics of human metapneumovirus infections in Central China post COVID-19 pandemic: a retrospective analysis.
• 4.   Nandhini G., Sujatha S., Jain N., Dhodapkar R., Tamilarasu K., Krishnamurthy S., Biswal N. Prevalence of Human metapneumovirus infection among patients with influenza-like illness: Report from a Tertiary Care Centre, Southern India. Indian journal of medical microbiology. 2016 Jan 1; 34(1):27-32.
• 5.   Haas L.E., Thijsen S.F., Van Elden L., Heemstra K.A. Human metapneumovirus in adults. Viruses. 2013 Jan 8; 5(1):87-110.
• 6.   Williams J.V., Edwards K.M., Weinberg G.A., Griffin M.R., Hall C.B., Zhu Y., Szilagyi P.G., Wang C.K., Yang C.F., Silva D., Ye D. Populationbased incidence of human metapneumovirus infection among hospitalized children. The Journal of infectious diseases. 2010 Jun 15; 201(12):1890-8.
• 7.   Scotta M.C., Chakr V.C., de Moura A., Becker R.G., de Souza A.P., Jones M.H., Pinto L.A., Sarria E.E., Pitrez P.M., Stein R.T., Mattiello R. Respiratory viral coinfection and disease severity in children: a systematic review and meta-analysis. Journal of Clinical Virology. 2016 Jul 1; 80:45-56.
• 8.   Taylor A., Whittaker E. The changing epidemiology of respiratory viruses in children during the COVID-19 pandemic: a canary in a COVID time. The Pediatric Infectious Disease Journal. 2022 Feb 1; 41(2):e46-8.
• 9.   Foley D.A., Sikazwe C.T., Minney-Smith CA, Ernst T., Moore H.C., Nicol M.P., Smith DW, Levy A., Blyth C.C. An unusual resurgence of human metapneumovirus in Western Australia following the reduction of non-pharmaceutical interventions to prevent SARS-CoV-2 transmission. Viruses. 2022 Sep 28; 14(10):2135.
• 10.   Kivit C.M., Groen K., Jongbloed M., Linssen C.F., van Loo A., van Gorp E.C., van Nieuwkoop S, van den Hoogen BG, de Kruif M.D. An off-season outbreak of human metapneumovirus infections after ending of a COVID-19 lockdown. Journal of Infection. 2022 May 1; 84(5):722-46.
• 11.   Nygaard U., Holm M., Rabie H., Rytter M. The pattern of childhood infections during and after the COVID-19 pandemic. The Lancet Child & Adolescent Health. 2024 Dec 1; 8(12):910-20.
• 12.   Contes K., Liu B.M. Epidemiology, clinical significance and diagnosis of respiratory viruses and their co-infections in the post-COVID era. Preprints. 2024:2024120268.
• 13.   Maltezou H.C., Papanikolopoulou A., Vassiliu S., Theodoridou K., Nikolopoulou G., Sipsas N.V. COVID-19 and respiratory virus co-infections: a systematic review of the literature. Viruses. 2023 Mar 28; 15(4):865.
• 14.   Kumar P., Srivastava M. Prophylactic and therapeutic approaches for human metapneumovirus. Virusdisease. 2018 Dec; 29(4):434-44.
• 15.   Yan H., Zhai B., Yang F., Wang P., Zhou Y. The Impact of Non-pharmacological Interventions Measures Against COVID-19 on Respiratory Virus in Preschool Children in Henan, China. Journal of Epidemiology and Global Health. 2024 Mar; 14(1):54-62.
• 16.   Al Mamun A., Hapsari R.N. Human Metapneumovirus (HMPV) Outbreaks in Focus: A call for Preparedness and Action. Health Dynamics. 2025 Jan 14; 2(1):1-3.
• 17.   Georgakopoulou V.E. Insights from respiratory virus co-infections. World Journal of Virology. 2024 Dec 25; 13(4):98600.

Data Sharing Statement

Funding